Roche’s Kadcyla wins NICE backing in early breast cancer use

The antibody-drug conjugate Kadcyla that targets HER2-positive cancer did not have any problems with England's National Health Service watch dog on any drugs that cost over $50,000. Previously, England rejected Kadcyla, which was approved for pateints with metastatic breast cancer because the drug only offers you 6 months to 1 year survival yet costs close to $90,000 per treatment cycle. That is outrageous! Roche had to make a deal to lower the cost and the details are confidential. Kadcyla is now approved for early treatment of breast cancer. This time Roche must have made a better deal right away with England as there was no problem this time around. Read more here. https://www.fiercepharma.com

/marketing/roche-s-kadcyla-wins-nice-backing-early-breast-cancer-use?mkt_tok=eyJpIjoiTUdNd1pUTXdOakJtWTJWbCIsInQiOiJHaWluVU5IMytwVmQwbEVPTkpOVzVQdnZiZUZwY3JiWXE5R2NYd2ZYNkkrYXBPditcL25JK1cxcTZpblFTUWk4bXVUMnZ5dWI0Q2xlNWU1RG9sY2E5ZmZJVXBzT3U4MzRlbERCUnZkUDJaOEwzVklOXC9XSEtWNjJBQStwdTlZdGN5Z29BdXFjM1BDRmVmN1RvTDJJejV5dz09In0%3D&mrkid=58020388